16.04.2015 MeVis Medical Solutions AG  DE000A0LBFE4

DGAP-News: MeVis Medical Solutions AG: Changes in the Supervisory Board of MeVis Medical Solutions AG


 
DGAP-News: MeVis Medical Solutions AG / Key word(s): Change of Personnel MeVis Medical Solutions AG: Changes in the Supervisory Board of MeVis Medical Solutions AG 16.04.2015 / 11:05 --------------------------------------------------------------------- - Prof. Dr. Peitgen and Mr. Kuhlmann-Lehmkuhle resign from office in light of the acquisition of a majority stake by Varian Medical Systems - Succession candidates proposed - Dr. Kruse remains Supervisory Board Member - Election of two new Supervisory Board Members at the AGM on June 9th. Bremen, April 16, 2015 - Prof. Dr. Heinz-Otto Peitgen, Chairman of the Supervisory Board of MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], and Mr. Peter Kuhlmann-Lehmkuhle, Member of the Supervisory Board of MeVis Medical Solutions AG, informed the Company this past Friday that, in light of the acquisition of a majority stake in the Company by VMS Deutschland Holdings GmbH, they will resign from their respective offices effective as of the end of the Annual General Meeting on June 9, 2015. Two succession candidates with executive positions at Varian are being proposed. Prof. Dr. Peitgen, Chairman of the Supervisory Board of MeVis Medical Solutions AG since September 2006, is one of the founders of the Company and has significantly influenced the development of MeVis Medical Solutions AG to become one of the world's leading software companies in medical imaging for diagnosis and treatment of cancer. During his time as Chairman of the Supervisory Board, the IPO of MeVis Medical Solutions AG was successfully implemented on November 16, 2007. Mr. Kuhlmann-Lehmkuhle has been a Member of the Supervisory Board since June 2011. "I founded MeVis with some of my employees in 1997 and accompanied it through 18 years in good and in challenging times," says Prof. Dr. Peitgen. "I am pleased that now, with me having reached the age of 70, MeVis, a healthy company with excellent annual results, is in very good hands through the acquisition of a majority of shares by Varian Medical Systems, and thus has the opportunity to expand its position in the world market. Today I thank especially the staff and the Executive Board, who have made the company what it is today, and I wish them all the best for the future." The Executive Board would like to thank Prof. Dr. Peitgen sincerely for many years of extraordinary commitment as founder and Chairman of the Supervisory Board of the Company. The Executive Board also thanks Mr. Kuhlmann-Lehmkuhle for his constructive contributions over the past four years. The Supervisory Board has decided to propose Mr. Jörg Fässler and Mr. Glen Hilton, both in responsible executive positions at Varian Medical Systems, as Members of the Supervisory Board at the Annual General Meeting on June 9, 2015. Dr. Jens Kruse will remain a Member of the Supervisory Board. --------------------------------------------------------------------- 16.04.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: MeVis Medical Solutions AG Caroline-Herschel-Str. 1 28359 Bremen Germany Phone: +49 421 224 95 0 Fax: +49 421 224 95 999 E-mail: [email protected] Internet: http://www.mevis.de ISIN: DE000A0LBFE4 WKN: A0LBFE Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 344867 16.04.2015


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 18,54 16,76 18,07 17,13 16,21 18,76 17,34
EBITDA1,2 9,18 7,60 8,25 5,97 4,77 7,99 3,99
EBITDA-Marge3 49,51 45,35 45,66 34,85 29,43 42,59
EBIT1,4 7,96 6,69 8,00 5,81 4,64 7,90 3,89
EBIT-Marge5 42,93 39,92 44,27 33,92 28,62 42,11 22,43
Jahresüberschuss1 5,62 7,17 8,07 5,70 4,55 7,79 4,92
Netto-Marge6 30,31 42,78 44,66 33,27 28,07 41,52 28,37
Cashflow1,7 7,32 5,52 6,55 2,89 9,13 4,86 5,85
Ergebnis je Aktie8 3,09 3,94 4,43 3,13 2,50 4,28 2,70
Dividende8 0,95 0,95 0,95 0,95 0,95 0,95 0,95
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Deloitte

INVESTOR-INFORMATIONEN
©boersengefluester.de
MeVis Med. Solutions
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0LBFE 25,000 Halten 45,50
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
10,42 10,26 1,02 7,62
KBV KCV KUV EV/EBITDA
2,55 7,77 2,62 10,61
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,95 0,95 3,80 19.03.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
- 27.05.2024 - 29.01.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
0,32% -8,48% -0,79% -30,17%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu MeVis Medical Solutions AG  ISIN: DE000A0LBFE4 können Sie bei EQS abrufen


Medtech , A0LBFE , M3V , XETR:M3V